Overview

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease. The study aims to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in comparison to imatinib alone to warrant further evaluation as a first line treatment for metastatic GIST.

Phase:

Phase 2

Details

Lead Sponsor:

Australasian Gastro-Intestinal Trials Group

Collaborators:

European Organisation for Research and Treatment of Cancer - EORTC
Scandinavian Sarcoma Group

Treatments:

Imatinib Mesylate